Cargando…

P029: Regional differences in Clostridium difficile infections (CDI) in relation to fluoroquinolone (FQ) and proton pump inhibitor (PPI) use, Finland, 2008-2011

Detalles Bibliográficos
Autores principales:	Kanerva, M, Ollgren, J, Voipio, T, Mentula, S, Lyytikäinen, O
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3688128/ http://dx.doi.org/10.1186/2047-2994-2-S1-P29

Ejemplares similares

Community- and Healthcare-Associated Clostridium difficile Infections, Finland, 2008−2013
por: Kotila, Saara M., et al.
Publicado: (2016)

Community- vs. healthcare-associated Clostridium difficile infections, Finland, 2008-2013: incidence, case fatality and genotypes
por: Kotila, SM, et al.
Publicado: (2015)

Surveillance of Clostridium difficile infections in Finnish acute care hospitals, 2008-2014: trends, diagnostics and control measures
por: Arifulla, DK, et al.
Publicado: (2015)

P028: Examining the relationship between fluoroquinolone use and Clostridium difficile infections (CDI): a meta-analysis
por: Formanek, MB, et al.
Publicado: (2013)

New advances in the treatment of Clostridium difficile infection (CDI)
por: Hedge, Dennis D, et al.
Publicado: (2008)

Estimating the burden of healthcare-associated infections caused by selected multidrug-resistant bacteria Finland, 2010
por: Kanerva, Mari, et al.
Publicado: (2012)

Hospitalizations and Deaths Associated with Clostridium difficile Infection, Finland, 1996–2004
por: Lyytikäinen, Outi, et al.
Publicado: (2009)

Fluoroquinolone Resistance and Clostridium difficile, Germany
por: Zaiß, Nils Henning, et al.
Publicado: (2010)

1115. Use of a Fluoroquinolone (FQ) vs. a Non-Fluoroquinolone (Non-FQ)-Based Antibiotic Regimen in the Treatment of Acute, Uncomplicated Diverticulitis
por: Mourani, Jessyca, et al.
Publicado: (2018)

SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI
por: Sattar, Abdul, et al.
Publicado: (2015)

2365. Volatile Metabolite-Based Detection of Clostridium difficile Infection (CDI)
por: Aloum, Obadah, et al.
Publicado: (2019)

Fluoroquinolone Use and Clostridium difficile–Associated Diarrhea
por: McCusker, Margaret E., et al.
Publicado: (2003)

2092. Acceptability and Effectiveness of Implementation Strategies on Fluoroquinolone (FQ) Prescribing
por: Suda, Katie J, et al.
Publicado: (2019)

Use of Electronic Data to Identify Risk Factors Associated with Clostridium difficile Infection (CDI) and to Develop CDI Risk Scores
por: Aukes, Laurie, et al.
Publicado: (2017)

Bezlotoxumab (BEZ) for Prevention of Clostridium Difficile Infection (CDI) Recurrence (rCDI): Outcomes in Patients with Substantial Renal Impairment (SRI)
por: Golan, Yoav, et al.
Publicado: (2017)

The burden of clostridium difficile infection: estimates of the incidence of CDI from U.S. Administrative databases
por: Olsen, Margaret A., et al.
Publicado: (2016)

527 Age-Related Changes in the Incidence of Community-Associated Clostridium Difficile Infection (CDI)
por: Faden, Howard
Publicado: (2014)

485. On- and Post-Antibiotic Effects on the Risk of Hospital-Acquired Clostridium difficile Infection (CDI)
por: Stevens, Vanessa, et al.
Publicado: (2018)

Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI
por: Louie, Thomas J., et al.
Publicado: (2012)

Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study
por: Zilberberg, Marya D, et al.
Publicado: (2014)

Bezlotoxumab (BEZ) for Prevention of Clostridium difficile Infection (CDI) Recurrence (rCDI): Distinguishing Relapse from Reinfection with Whole Genome Sequencing (WGS)
por: Dorr, Mary Beth, et al.
Publicado: (2017)

National antimicrobial stewardship and fluoroquinolone-resistant Clostridium difficile in China
por: Xiao, Meng, et al.
Publicado: (2017)

Fluoroquinolone (FQ) utilization in symptomatic bacteriuria (SB) due to E. coli and rate of FQ-resistant E. coli in a teaching psychiatric hospital
por: Westphal, F, et al.
Publicado: (2011)

Clostridium difficile infections in teaching hospital in northern Finland
por: Marttila-Vaara, M., et al.
Publicado: (2019)

973 Use of Concomitant Antibiotics During Treatment for Clostridium difficile Infection (CDI) in Pediatric Inpatients
por: Stevens, Vanessa, et al.
Publicado: (2014)

467. Investigation of a Clostridium difficile Infection (CDI) Outbreak in a Community Teaching Hospital
por: Parker, Laura, et al.
Publicado: (2018)

Reductions in inpatient fluoroquinolone use and postdischarge Clostridioides difficile infection (CDI) from a systemwide antimicrobial stewardship intervention
por: Jones, K. Ashley, et al.
Publicado: (2021)

gyrA Mutations in Fluoroquinolone-resistant Clostridium difficile PCR-027
por: Drudy, Denise, et al.
Publicado: (2007)

Calprotectin and Lactoferrin Faecal Levels in Patients with Clostridium difficile Infection (CDI): A Prospective Cohort Study
por: Swale, Andrew, et al.
Publicado: (2014)

Applying fecal microbiota transplantation (FMT) to treat recurrent Clostridium difficile infections (rCDI) in children
por: Fareed, Shaaz, et al.
Publicado: (2018)

Are Patients with Prior Clostridium difficile Infection (CDI) a Potential Source of Transmission during Hospital Admissions?
por: Gonzalez-Orta, Melany, et al.
Publicado: (2017)

Predictors of 30-day All-cause Mortality in Veterans with First Recurrence of Clostridium difficile Infection (CDI)
por: Morrill, Haley, et al.
Publicado: (2017)

1980. Efficacy of an Oral Vancomycin Loading Dose (LD) in the Treatment of Confirmed Clostridium Difficile Infection (CDI)
por: Tirmizi, Samad, et al.
Publicado: (2018)

1122. Evaluation of Fecal Microbiota Transplant (FMT) in Elderly Patients With recurrent Clostridium difficile Infection (CDI)
por: Hassoun, Ali, et al.
Publicado: (2018)

Clostridium difficile Infection–Daily Symptoms (CDI-DaySyms™) questionnaire: psychometric characteristics and responder thresholds
por: Talbot, George H., et al.
Publicado: (2019)

O063: Healthcare-associated bloodstream infections in Finland, 1999-2011 – adjusted ranking of hospitals by Staphylococcus aureus rates
por: Kärki, T, et al.
Publicado: (2013)

Intravenous Tigecycline Facilitates Cure of Severe Clostridium difficile Infection (CDI) After Failure of Standard Therapy: A Case Report and Literature Review of Tigecycline Use in CDI
por: Navalkele, Bhagyashri D., et al.
Publicado: (2016)

Use of Concomitant Antibiotics During Treatment for Clostridium difficile Infection (CDI) in Pediatric Inpatients: An Observational Cohort Study
por: Stevens, Vanessa W., et al.
Publicado: (2016)

Declining Rates of Clostridium difficile infections (CDI) in Veterans Affairs (VA) Long-term Care Facilities (LTCF)
por: Evans, Martin, et al.
Publicado: (2017)

470. Concomitant Antibiotic Use and Death Among a National Cohort of Veterans With Clostridium difficile Infection (CDI)
por: Appaneal, Haley, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hbtvikl0e0lrvvsc6e3oikub12